|1.||Weisgraber, Karl H: 7 articles (01/2011 - 08/2005)|
|2.||Huang, Yadong: 7 articles (08/2009 - 01/2006)|
|3.||Michaelson, Daniel M: 6 articles (01/2015 - 02/2003)|
|4.||Vitek, Michael P: 5 articles (01/2014 - 01/2006)|
|5.||Bu, Guojun: 4 articles (05/2015 - 01/2014)|
|6.||Phillips, Michael C: 4 articles (09/2014 - 03/2008)|
|7.||Huebbe, Patricia: 4 articles (05/2014 - 10/2011)|
|8.||Rimbach, Gerald: 4 articles (05/2014 - 10/2011)|
|9.||Raber, Jacob: 4 articles (04/2013 - 06/2002)|
|10.||Owen, James S: 4 articles (04/2011 - 01/2005)|
09/01/2011 - "The pharmacologic efficacy of QC/isoQC-inhibition was assessed in accelerated atherosclerosis in ApoE3*Leiden mice, showing attenuated atherosclerotic pathology following chronic oral treatment. "
08/01/2005 - "Because the dynamic range of human CRP is much larger, apolipoprotein E*3-Leiden (E3L) transgenic mice carrying the human CRP gene offer a unique model to study the role(s) of CRP in atherosclerosis development. "
03/16/2007 - "In contrast, atherosclerosis in Apoe3/3 Ldlr-/- mice, expressing the human apoE3 isoform, did not differ by the levels of macrophage LDLr expression. "
01/05/2001 - "One group of mice was sacrificed for evaluation of atherosclerosis at base line, and two other groups were injected with a second generation adenoviruses encoding human apoE3 or a control empty virus. "
07/01/1983 - "On the other hand, apolipoprotein E3/2 heterozygosity may have a protective effect on the development of early atherosclerosis."
01/01/2011 - "Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia."
01/01/2011 - "In the normal population, ApoE3 isoform is the most prevalent, and ApoE2 or E4 is frequently associated with hyperlipoproteinemia. "
09/01/2003 - "The authors suggest that presence of apo E3/3 genotype cannot rule out the diagnosis of type III hyperlipoproteinemia and LPG. "
07/01/1999 - "To investigate a pathophysiological relevance, the effect of LPL and normal apo E-3 was compared to LPL and four apo E variants, associated with type III hyperlipoproteinemia (HLP). "
05/01/1996 - "Familial type V hyperlipoproteinemia with hyper-remnant-like particle-cholesterol accompanied with apolipoprotein E3/E4 phenotype."
|3.||Body Weight (Weight, Body)
10/01/2015 - "Seven-month-old targeted replacement apoE3 and C57BL/6N male mice were orally exposed to CPF at 0 or 2mg/kg body weight/day for 8 consecutive weeks. "
05/15/2015 - "Dietary CPF challenge increased body weight only in apoE3 mice. "
01/01/2013 - "Nine young healthy Japanese women with a normal weight (body mass index: 18.5≤-< 25 kg/m(2)), a normal ovarian cycle and an apolipoprotein E 3/3 phenotype were enrolled as participants and studied on four occasions. "
06/01/2007 - "Eighty-eight APO E3/3 volunteers [67 with (-1131T and 56C) APOA5*1 haplotype, 12 with (-1131C and 56C) APOA5*2 haplotype, and nine with (-1131T and 56G) APOA5*3 haplotype] underwent a fat load test consisting of the consumption of 1 g of fat per kilogram body weight and 60,000 IU vitamin A. "
08/10/2012 - "The initial study confirmed previous reports that APOE4 gene replacement mice were less sensitive than APOE3 mice to diet-induced body weight gain but exhibited hyperinsulinemia, and their adipose tissues were similarly inflamed as those in APOE3 mice. "
|4.||Atherosclerotic Plaque (Atheroma)
01/01/2002 - "Up to 3 months after a single administration of rAAV/apoE3, a significant reduction in atherosclerotic plaque density in aortas of treated animals was observed (approximately 30%), indicating that low-level rAAV-mediated apoE3 expression from skeletal muscle can retard atherosclerotic progression in this well-defined genetic model."
04/01/2011 - "AAV2/9 was notably less effective, mice having a 3-fold lower level of plasma apoE3 at 13 weeks and a 50% greater burden of atherosclerotic plaque lipid in their brachiocephalic arteries. "
05/01/2008 - "The global atheroma burden index was similarly higher in the apoE4 group than in the apoE3 group (p=0.033). "
03/16/2007 - "Our results demonstrate that apoE4, but not apoE3, in macrophages enhances atherosclerotic plaque development in mice in an LDLr-dependent manner and suggests that this interaction may contribute to the association of apoE4 with an increased cardiovascular risk in humans."
01/01/2015 - "Gene therapy, specifically cationic-liposome mediated APOE3 gene transfer to the CNS cells by plasmid vector, decreased a TBI-induced death of neurons and improved qualitative composition of neuronal population, normalized neuron-glial relations, decreased gliosis and microglial activation, axonal damage, myelin destruction and lipofuscin accumulation, all these having age-related peculiarities. "
06/01/2005 - "Using homozygous human apolipoprotein E2 (apoE2) (2/2)-, apoE3 (3/3)-, or apoE4 (4/4)-knock-in (KI) mice, we have shown that delayed infarct expansion and reactive astrocytosis after permanent middle cerebral artery occlusion (pMCAO) were markedly exacerbated in 4/4-KI mice as compared with 2/2- or 3/3-KI mice. "
|1.||Apolipoproteins E (ApoE)
|7.||Apolipoproteins B (ApoB)
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)